IL116730A0 - Chemically modified interferon - Google Patents

Chemically modified interferon

Info

Publication number
IL116730A0
IL116730A0 IL11673096A IL11673096A IL116730A0 IL 116730 A0 IL116730 A0 IL 116730A0 IL 11673096 A IL11673096 A IL 11673096A IL 11673096 A IL11673096 A IL 11673096A IL 116730 A0 IL116730 A0 IL 116730A0
Authority
IL
Israel
Prior art keywords
chemically modified
modified interferon
interferon
chemically
modified
Prior art date
Application number
IL11673096A
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of IL116730A0 publication Critical patent/IL116730A0/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/555Interferons [IFN]
    • C07K14/56IFN-alpha
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19Cytokines; Lymphokines; Interferons
    • A61K38/21Interferons [IFN]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
IL11673096A 1995-01-13 1996-01-10 Chemically modified interferon IL116730A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US37247895A 1995-01-13 1995-01-13

Publications (1)

Publication Number Publication Date
IL116730A0 true IL116730A0 (en) 1996-05-14

Family

ID=23468282

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11673096A IL116730A0 (en) 1995-01-13 1996-01-10 Chemically modified interferon

Country Status (9)

Country Link
EP (1) EP0804248A2 (en)
JP (1) JPH10513440A (en)
KR (1) KR19980701814A (en)
AU (1) AU4751896A (en)
BR (1) BR9607599A (en)
CA (1) CA2209557A1 (en)
IL (1) IL116730A0 (en)
WO (1) WO1996021468A2 (en)
ZA (1) ZA96206B (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105131104B (en) * 2001-10-10 2018-11-16 诺和诺德公司 The reconstruct and sugar conjugation of peptide
WO2006127896A2 (en) 2005-05-25 2006-11-30 Neose Technologies, Inc. Glycopegylated factor ix
EP2338333B1 (en) 2003-04-09 2017-09-06 ratiopharm GmbH Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
TWI375679B (en) 2003-10-14 2012-11-01 Hoffmann La Roche Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
JP5948627B2 (en) 2004-10-29 2016-07-20 レイショファーム ゲーエムベーハー Fibroblast growth factor (FGF) remodeling and carbohydrate pegylation
EP2514757A3 (en) 2005-01-10 2014-03-05 ratiopharm GmbH Glycopegylated granulocyte colony stimulating factor
US9187546B2 (en) 2005-04-08 2015-11-17 Novo Nordisk A/S Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
NZ565059A (en) 2005-07-25 2011-08-26 Intermune Inc Novel macrocyclic inhibitors of hepatitus C virus replication
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
JP2009511595A (en) 2005-10-11 2009-03-19 インターミューン・インコーポレーテッド Compounds and methods for inhibiting replication of hepatitis C virus
WO2007056191A2 (en) 2005-11-03 2007-05-18 Neose Technologies, Inc. Nucleotide sugar purification using membranes
AR078117A1 (en) 2006-06-20 2011-10-19 Protech Pharma S A A RECOMBINANT MUTEIN OF THE GLICOSILATED HUMAN ALPHA INTERFERON, A CODIFYING GENE FOR SUCH MUTEIN, A METHOD OF PRODUCTION OF SUCH GENE, A METHOD FOR OBTAINING A EUCARIOTE CELL MANUFACTURING THIS MUTEINE, A METHOD FOR A MUTE DIFFERENT PROCEDURE
WO2008011633A2 (en) 2006-07-21 2008-01-24 Neose Technologies, Inc. Glycosylation of peptides via o-linked glycosylation sequences
US20100075375A1 (en) 2006-10-03 2010-03-25 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
KR20100016160A (en) 2007-04-03 2010-02-12 바이오제너릭스 에이지 Methods of treatment using glycopegylated g-csf
JP5876649B2 (en) 2007-06-12 2016-03-02 ラツィオファルム ゲーエムベーハーratiopharm GmbH Improved process for producing nucleotide sugars
WO2009108806A1 (en) 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
US20110027229A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
CN102711871A (en) 2010-06-16 2012-10-03 麦德托尼克公司 Damping systems for stabilizing medications in drug delivery devices

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5372808A (en) * 1990-10-17 1994-12-13 Amgen Inc. Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect
KR950014915B1 (en) * 1991-06-19 1995-12-18 주식회사녹십자 Asialoglycoprotein-conjugated compounds
TW263437B (en) * 1992-09-24 1995-11-21 Takeda Pharm Industry Co Ltd
CN1087093A (en) * 1993-09-16 1994-05-25 华西医科大学药学院 The galactosyl interferon conjugate of liver target

Also Published As

Publication number Publication date
WO1996021468A2 (en) 1996-07-18
JPH10513440A (en) 1998-12-22
BR9607599A (en) 1998-06-09
MX9705119A (en) 1997-10-31
EP0804248A2 (en) 1997-11-05
ZA96206B (en) 1996-08-19
AU4751896A (en) 1996-07-31
WO1996021468A3 (en) 1996-09-12
KR19980701814A (en) 1998-06-25
CA2209557A1 (en) 1996-07-18

Similar Documents

Publication Publication Date Title
HUP9600857A3 (en) Interferon solution
ZA96206B (en) Chemically modified interferon
DE59607964D1 (en) Oxymethoxy-3-aryl-pyron-derivate
DE59607241D1 (en) Endotracheal-tubus
GB9503549D0 (en) Binlatch
DE59602888D1 (en) Breitstreckaggregat
DE59605001D1 (en) Luftreinigungsgerät
DE59602283D1 (en) Inchbremseinrichtung
DE59602030D1 (en) Zellige polyurethan-elastomere
EP0747060A3 (en) Anti-plasma-antibody-preparation
ZA964817B (en) Centrifugal-separator
DE59505396D1 (en) Handhobelmaschine
AP9600802A0 (en) Libricant
DE59604506D1 (en) Rückkühlsystem
DE59600830D1 (en) Breitstrahldüse
DE59604913D1 (en) Carbonylverbindungen
CA76097S (en) Can
AU127800S (en) Gamesboard
AU125853S (en) Tea - towel
AU130380S (en) Matting-tile
AU129378S (en) TeleChipper
AU131835S (en) Gamesboard
AU128041S (en) Gamesboard
AU127251S (en) Sandboard
AU126858S (en) Billycart